# A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer

> **NCT04516447** · PHASE1 · RECRUITING · sponsor: **K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc** · enrollment: 172 (estimated)

## Conditions studied

- Solid Tumor
- Epithelial Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Cancer

## Interventions

- **DRUG:** Azenosertib
- **DRUG:** Carboplatin
- **DRUG:** Pegylated liposomal doxorubicin
- **DRUG:** Paclitaxel
- **DRUG:** Gemcitabine
- **BIOLOGICAL:** Bevacizumab

## Key facts

- **NCT ID:** NCT04516447
- **Lead sponsor:** K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-10-26
- **Primary completion:** 2028-06-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 172 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04516447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04516447, "A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT04516447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*